What’s next for vaginal ‘rejuvenation’?

August 31, 2018

In late July, the FDA released a safety communication warning against the use of energy-based devices to treat a host of vaginal conditions and symptoms that fall under vaginal “rejuvenation.”  The purpose of the FDA communication was to “Alert patients and healthcare providers that the use of energy-based devices to perform vaginal ‘rejuvenation,’ cosmetic vaginal procedures, or non-surgical vaginal procedures to treat symptoms related to menopause, urinary incontinence, or sexual function may be associated with serious adverse events. The safety and effectiveness of energy-based devices for treatment of these conditions has not been established.”
The FDA’s focus is on nonsurgical procedures providers perform to treat vaginal laxity; vaginal atrophy, dryness or itchiness; pain during sexual intercourse; pain during urination; decreased sexual sensation; and more. 
Read more at The Aesthetic Channel >>

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Dermalogica Launches FDA-Cleared PRO Pen Microneedling System
    • Regenerative Aesthetics Is Evolving. Are You Keeping Up?
    • Influx Marketing Introduces Growthstack, a New All-In-One Growth Platform Built for Med Spas
    • AbbVie Receives FDA Complete Response Letter for TrenibotulinumtoxinE
    • ByrdAdatto Named to D Magazine’s 2026 Best Lawyers in Dallas List